| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 315.416 | 311.061 | 270.441 | 232.793 | 236.730 | 246.853 | 216.889 | 239.501 | 222.420 | 270.802 |
| Total Income - EUR | 315.863 | 311.273 | 277.275 | 235.310 | 239.987 | 247.597 | 216.951 | 239.761 | 222.935 | 271.802 |
| Total Expenses - EUR | 312.250 | 310.974 | 279.651 | 230.941 | 233.517 | 243.753 | 215.630 | 238.335 | 225.861 | 267.058 |
| Gross Profit/Loss - EUR | 3.614 | 299 | -2.376 | 4.369 | 6.470 | 3.844 | 1.320 | 1.426 | -2.926 | 4.744 |
| Net Profit/Loss - EUR | 3.025 | 230 | -3.117 | 3.610 | 5.486 | 3.393 | 1.320 | 1.426 | -2.926 | 4.449 |
| Employees | 5 | 5 | 5 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
Check the financial reports for the company - Medofarm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 1.101 | 1.552 | 2.817 | 2.002 | 1.213 | 571 | 141 | 466 |
| Current Assets | 128.502 | 97.883 | 107.811 | 89.063 | 94.111 | 89.596 | 87.517 | 97.754 | 75.411 | 82.125 |
| Inventories | 28.055 | 26.865 | 30.000 | 20.899 | 31.295 | 34.852 | 41.210 | 42.874 | 42.862 | 33.619 |
| Receivables | 48.533 | 22.111 | 36.887 | 43.151 | 37.489 | 40.598 | 32.180 | 43.678 | 30.154 | 38.670 |
| Cash | 51.914 | 48.907 | 40.924 | 25.013 | 25.326 | 14.147 | 14.127 | 11.202 | 2.394 | 9.836 |
| Shareholders Funds | 7.123 | 4.287 | 10.591 | 14.006 | 18.874 | 16.844 | 14.661 | 14.808 | 10.416 | 14.807 |
| Social Capital | 360 | 356 | 10.070 | 9.885 | 9.694 | 9.510 | 9.299 | 9.328 | 9.300 | 9.248 |
| Debts | 121.379 | 93.596 | 98.321 | 77.623 | 78.778 | 75.208 | 74.335 | 83.600 | 65.151 | 67.784 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Medofarm S.r.l.